Repligen (RGEN) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue was $167.5M–$168M, with full-year revenue of $634.4M, meeting guidance despite FX headwinds.

• Non-COVID Q4 revenue grew 13% year-over-year; full-year non-COVID revenue up 3%.

• Orders in Q4 were the highest since Q2 2022, outpacing revenue by 6%, with strong performance from Filtration, Analytics, CDMO, and equipment.

• Strategic priorities for 2025 include accelerating growth, innovation, margin expansion, M&A, and organizational readiness.

• Closed Tantti Laboratory Inc acquisition, expanding Protein and Chromatography offerings.

Financial highlights

• Q4 adjusted gross margin: 50.7%; adjusted operating margin: 14.9%; adjusted EBITDA margin: 20.9%.

• Full-year adjusted gross margin expanded by 140 bps to 50.4%.

• Adjusted net income for 2024: $89M, down 5% year-over-year; adjusted EPS: $1.58.

• Cash and cash equivalents at year-end: $757M; $178M cash flow from operations, up 56% from 2023.

• Q4 GAAP net loss was $(34)M; full year GAAP net loss was $(26)M.

Outlook and guidance

• 2025 revenue guidance: $685M–$710M, up 8%–12% reported, 10%–14% ex-COVID.

• Adjusted gross margin expected at 51%–52%; adjusted operating margin at 14%–15%; adjusted EBITDA margin at 20%–21%.

• Adjusted EPS guidance: $1.67–$1.76; CapEx to decline 20%–25% from 2024.

• H2 2025 expected to be stronger than H1, with Q1 as the weakest quarter.